Skip to main content

Articles By Janet Pope, MD, MPH, FRCPC

heart.jpg (keep)

CV risk factors not equal when considering magnitude of risk

What can we learn from Oral Surveillance? The Oral Surveillance trial has almost become a household word for rheumatologists.

Read Article
TYK2i

Are TYK2 inhibitors ‘ticked’ to be part of the JAK family?

Are TYK2 inhibitors JAK inhibitors? Are they effective in PsA? Are they safer than JAKi? Read on to learn more.

Read Article
heart.jpg (keep)

Best of 2021: Perspectives on CV safety: JAKi (Tofacitinib) and TNF inhibitors

Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.

Read Article
Giant-Cell_Vasculitis.jpg

Top vasculitis takeaways from ACR 2021

There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis. 

Read Article
heart.jpg (keep)

Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors

Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Racial/ethnic disparity in U.S. lupus nephritis mortality

At #ACR21, the plenary session included an analysis of deaths from SLE throughout the US comparing 1999 to 2019 (Abstract #0454).

Read Article
yes, no, maybe

Reader beware! Interpretation of effectiveness & safety of JAKi vs bDMARDs in real world data

Multiple studies compared effectiveness, retention and/or safety of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) at EULAR 2021.

Read Article
light-bulbs-1125016_640.jpg

Lessons learned in SLE

An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351).

Read Article
Telemedicine.MD.Computer.phone (keep)

How are RA patients doing using telemedicine/virtual care?

Rheumatologists switched their practices overnight from primarily in person to nearly all virtual care as COVID-19 pandemic geared up in March 2020 and then to a blend of in person and virtual care. How are RA patients doing?

Read Article
Lknee.OA_.jpg

What’s new in knee osteoarthritis that matters?

Are intra-articular steroid injections effective in symptomatic knee OA? Do they accelerate cartilage loss? Does weight less actually help? Do we have DMARDs for knee OA? Insights from 2020 ACR Convergence.

Read Article